NantKwest Inc (NK):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NantKwest Inc (NK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8215
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NantKwest Inc (NantKwest), a subsidiary of NantWorks LLC, formerly Conkwest Inc, is a clinical-stage immunotherapy company that develops therapeutic treatments for cancer, infectious diseases, and inflammatory diseases. The company utilizes its immuno-oncology NK platform to destroy the tumor cells through direct killing or antibody-mediated killing or target activated killing. Its haNK, aNK and taNK platforms addresses the certain limitations of T cell therapies that include the reduction of risk of serious cytokine storms reported after T cell therapy. The company provides targeted therapeutic areas such as hematological cancers, solid tumors and cancer stem cells, viral, fungal and bacterial infections, inflammatory diseases, and others. The company operates through its offices located in Culver, Woburn, San Diego, the US, and others. NantKwest is headquartered in San Diego, California, the US.

NantKwest Inc (NK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
NantKwest Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises US$6.5 Million In Venture Financing 13
Partnerships 14
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
Licensing Agreements 18
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
Equity Offering 21
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Acquisition 27
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc – Key Competitors 29
NantKwest Inc – Key Employees 30
NantKwest Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jun 19, 2018: NantKwest Appoints Sonja Nelson As Chief Financial Officer 32
Sep 22, 2017: NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors 33
Product News 34
06/06/2017: NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease 34
Product Approvals 35
May 09, 2017: NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer 35
Mar 20, 2017: NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma 36
Clinical Trials 37
Feb 13, 2018: Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma 37
Oct 02, 2017: NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer Cells 38
Jul 31, 2017: NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies 39
Jan 23, 2017: Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer 40
Other Significant Developments 41
Jan 04, 2018: NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting A Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the Nant Cancer Vaccine 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
NantKwest Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises US$6.5 Million In Venture Financing 13
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc, Key Competitors 29
NantKwest Inc, Key Employees 30
NantKwest Inc, Other Locations 31
NantKwest Inc, Subsidiaries 31

List of Figures
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[NantKwest Inc (NK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Anhui Construction Engineering Group Co., Ltd.:企業の戦略・SWOT・財務情報
    Anhui Construction Engineering Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Anhui Construction Engineering Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Industrial and Commercial Bank of China Ltd:戦略・SWOT・企業財務分析
    Industrial and Commercial Bank of China Ltd - Strategy, SWOT and Corporate Finance Report Summary Industrial and Commercial Bank of China Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Reckitt Benckiser Group plc:企業のM&A・事業提携・投資動向
    Reckitt Benckiser Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Reckitt Benckiser Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Hindustan ZInc Ltd:企業の戦略・SWOT・財務情報
    Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • AIB Group Plc:企業の戦略・SWOT・財務情報
    AIB Group Plc - Strategy, SWOT and Corporate Finance Report Summary AIB Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Zynerba Pharmaceuticals Inc (ZYNE):企業の財務・戦略的SWOT分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-euphoric cannabinoid, formulate …
  • Profarma Distribuidora de Produtos Farmaceuticos SA (PFRM3):企業の財務・戦略的SWOT分析
    Profarma Distribuidora de Produtos Farmaceuticos SA (PFRM3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • Farbest-Tallman Foods Corp.:企業の戦略・SWOT・財務分析
    Farbest-Tallman Foods Corp. - Strategy, SWOT and Corporate Finance Report Summary Farbest-Tallman Foods Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Psychemedics Corp (PMD):企業の財務・戦略的SWOT分析
    Summary Psychemedics Corp (Psychemedics) is a clinical laboratory service provider. The company provides testing for drugs abuse using hair analysis. It offers drug panel, workplace drug testing, personal drug testing kits, school drug testing, alcohol testing, synthetic cannabinoids testing, benzod …
  • Turkiye Petrol Rafinerileri AS (TUPRS):企業の財務・戦略的SWOT分析
    Turkiye Petrol Rafinerileri AS (TUPRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Astex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Astex Pharmaceuticals Inc (Astex Pharmaceuticals), is a novel drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. It discovers and develops small molecule treatments. The company’s lead product, Dacogen (indicated for the treatment of myel …
  • Torchlight Energy Resources Inc (TRCH):企業の財務・戦略的SWOT分析
    Summary Torchlight Energy Resources Inc (Torchlight Energy), formerly Known as Pole Perfect Studios Inc, is an oil and gas exploration and production company. The company’s activities include acquisition, exploration and development of domestic oil fields. Its business process includes investment ev …
  • LMI Aerospace, Inc.:企業の戦略的SWOT分析
    LMI Aerospace, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Z Energy Ltd
    Z Energy Ltd - Strategy, SWOT and Corporate Finance Report Summary Z Energy Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Adimab LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Adimab LLC (Adimab) is an antibody discovery technology provider that provides antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic d …
  • Aptitude Medical Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aptitude Medical Systems Inc (Aptitude Medical) is a developer of dynamic proteins, lipids, sugars and metabolites. The company's target range comprises nonimmunogenic proteins, peptides, toxins, glycans, drugs, metabolites and small epitopes. Its integrated suite of proprietary technologies …
  • Rada Electronic Industries Ltd.
    Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Whirlpool Of India Limited:企業の戦略・SWOT・財務情報
    Whirlpool Of India Limited - Strategy, SWOT and Corporate Finance Report Summary Whirlpool Of India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Adisseo France SAS:企業の戦略的SWOT分析
    Adisseo France SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Nikkiso Co Ltd (6376):企業の製品パイプライン分析2018
    Summary Nikkiso Co., Ltd. (Nikkiso) is a diversified company that develops, manufactures and markets medical equipment and industrial instruments. The company’s product portfolio includes pumps, odorizing systems, metering and mixing systems, ceramic substrate production systems, water-conditioning …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆